Neornat Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Employees
  • 6

Employees

  • Latest Deal Type
  • Early Stage VC

  • Latest Deal Amount
  • $2.67M

  • Investors
  • 9

Neornat General Information

Description

Developer of neo-RNA therapeutics designed to offer anticancer drugs. The company uses data-based liver cancer diagnosis technology for macrophage immuno-oncology and RNA regulator-targeted anticancer with sensitivity and specificity, enabling medical professionals to offer patients effective treatment by early detection of liver cancer.

Contact Information

Website
neornat.com
Formerly Known As
Gecko Bio Lab, Gecko BioLab
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 47-3 Banpo-daero 39-gil
  • Seocho-gu, Seowoo Building, 2nd floor
  • Seoul, 06591
  • South Korea
+82
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 47-3 Banpo-daero 39-gil
  • Seocho-gu, Seowoo Building, 2nd floor
  • Seoul, 06591
  • South Korea
+82

Neornat Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Neornat Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Early Stage VC 01-Dec-2023 $2.67M Completed Generating Revenue
6. Accelerator/Incubator 01-May-2023 Completed Generating Revenue
5. Secondary Transaction - Private 01-May-2023 Completed Generating Revenue
4. Accelerator/Incubator 01-Nov-2022 Completed Generating Revenue
3. Early Stage VC (Series A) 28-Mar-2022 Completed Generating Revenue
2. Accelerator/Incubator 30-Apr-2021 $446K $446K Completed Generating Revenue
1. Seed Round 17-Mar-2021 Completed Generating Revenue
To view Neornat’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Neornat Patents

Neornat Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210254174-A1 Liver cancer-specific biomarker Inactive 14-Jun-2018

Neornat Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Neornat Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
Korea Technology Finance Government Minority
DB Financial Investment Asset Manager Minority
DTR Partners Venture Capital Minority
GeneN Investment Partners Venture Capital Minority
Tech Incubator Program for Startup Accelerator/Incubator
You’re viewing 5 of 9 investors. Get the full list »

Neornat FAQs

  • When was Neornat founded?

    Neornat was founded in 2020.

  • Where is Neornat headquartered?

    Neornat is headquartered in Seoul, South Korea.

  • What is the size of Neornat?

    Neornat has 6 total employees.

  • What industry is Neornat in?

    Neornat’s primary industry is Drug Discovery.

  • Is Neornat a private or public company?

    Neornat is a Private company.

  • What is Neornat’s current revenue?

    The current revenue for Neornat is .

  • How much funding has Neornat raised over time?

    Neornat has raised $3.19M.

  • Who are Neornat’s investors?

    Korea Technology Finance, DB Financial Investment, DTR Partners, GeneN Investment Partners, and Tech Incubator Program for Startup are 5 of 9 investors who have invested in Neornat.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process